Table 4.
Demographics of patient participants under immunomodulatory or antiviral medication, disease severity categories and symptoms, underlying conditions and medication
| Clinical data (%, n) | Immunomodulatory | Antiviral | ||
|---|---|---|---|---|
| Age (years) | 60.21 | (20–87) | 51.87 | (43–60) |
| Male (%) | 31% | 9 | 100% | 12 |
| Female (%) | 69% | 20 | 0% | 0 |
| Sample collection date | 6/4/2020 ‐ 12/8/2020 | 6/4/2020 ‐ 12/8/2020 | ||
| SARS‐CoV‐2 PCR+ | 100% | 100% | ||
| Seroconversion (Spike) | 28% | (8/29) | 75% | (9/12) |
| Seroconversion (RBD) | 31% | (9/29) | 75% | (9/12) |
| Disease Severity | ||||
| Asympomatic | 24% | 7 | 25% | 3 |
| Mild | 14% | 4 | 17% | 2 |
| Moderate | 59% | 17 | 58% | 7 |
| Severe | 3% | 1 | 0% | 0 |
| Symptoms | ||||
| Cough | 45% | 13 | 0% | 0 |
| Myalgia | 10% | 3 | 17% | 2 |
| Fever | 41% | 12 | 58% | 7 |
| Anosmia | 7% | 2 | 0% | 0 |
| Dyspnea | 31% | 9 | 42% | 5 |
| Diarrhea | 0% | 0 | 17% | 2 |
| Odynophagia | 0% | 0 | 0% | 0 |
| Hypogeusia | 0% | 0 | 0% | 0 |
| Headache | 7% | 2 | 17% | 2 |
| Rhinorrhea | 0% | 0 | 0% | 0 |
| Asthenia | 28% | 8 | 8% | 1 |
| Days Post Symptom onset at collection | 10.96 | (2‐35) | 9.00 | (3‐11) |
| PCR+ day to serum collection | 6.43 | (1‐13) | 6.17 | (1‐11) |
| Underlying conditions | ||||
| None | 0.00% | 0 | 0.00% | 0 |
| Chronic kidney disease | 17.24% | 5 | 25.00% | 3 |
| Diabetes | 17.24% | 5 | 16.67% | 2 |
| Hypertension | 34.48% | 10 | 16.67% | 2 |
| Heart disease | 6.90% | 2 | 0.00% | 0 |
| Alzheimer | 0.00% | 0 | 0.00% | 0 |
| Cerebrovascular disease | 3.45% | 1 | 0.00% | 0 |
| Dementia/Parkinson | 17.24% | 5 | 0.00% | 0 |
| Asthma | 0.00% | 0 | 0.00% | 0 |
| Cancer | 37.93% | 11 | 0.00% | 0 |
| COPD | 0.00% | 0 | 0.00% | 0 |
| HIV | 0.00% | 0 | 91.67% | 11 |
| SLE | 6.90% | 2 | 0.00% | 0 |
| Medication | ||||
| None | 0.00% | 0 | 0.00% | 0 |
| Midostaurin | 3.45% | 1 | 0.00% | 0 |
| Aciclovir | 3.45% | 1 | 0.00% | 0 |
| Tacrolimus | 17.24% | 5 | 0.00% | 0 |
| Prednisolone | 41.38% | 12 | 0.00% | 0 |
| Chemotherapy (Paclitaxel) | 6.90% | 2 | 0.00% | 0 |
| Methotrexate | 3.45% | 1 | 0.00% | 0 |
| Raltegravir | 0.00% | 0 | 25.00% | 3 |
| Darunavir/Cobicistat | 0.00% | 0 | 25.00% | 3 |
| Exemestane | 6.90% | 2 | 0.00% | 0 |
| Azathioprine | 10.34% | 3 | 0.00% | 0 |
| Dexamethasone | 3.45% | 1 | 0.00% | 0 |
| Tamoxifen | 6.90% | 2 | 0.00% | 0 |
| Abacavir | 0.00% | 0 | 33.33% | 4 |
| Lamivudina | 0.00% | 0 | 33.33% | 4 |
| Micofenolate | 6.90% | 2 | 0.00% | 0 |
| Entecavir | 0.00% | 0 | 8.33% | 1 |
| Dolutegravir | 0.00% | 0 | 25.00% | 3 |